THINQ PHARM-CRO PVT
GenericsTHINQ PHARM-CRO PVT is a generic drug manufacturer focused on Gastroenterology.
THINQ PHARM-CRO PVT's Key Drugs
THINQ PHARM-CRO PVT's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
THINQ PHARM-CRO PVT's Recent FDA Approvals
New NDA/BLA approvals for THINQ PHARM-CRO PVT over the last two years — novel drugs only, excluding generics and label supplements.
THINQ PHARM-CRO PVT's Therapeutic Areas
THINQ PHARM-CRO PVT's approved drugs and pipeline span 1 therapeutic area, led by Gastroenterology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
THINQ PHARM-CRO PVT's Top Competitors
THINQ PHARM-CRO PVT's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Bristol-Myers Squibb, and BAUSCH. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
THINQ PHARM-CRO PVT Pipeline Snapshot
Active clinical trials for THINQ PHARM-CRO PVT across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Gastroenterology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2019-08-30
- Latest
- 2024-12-10
- Applications
- 4